PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, and RxCrossroads™ by McKesson, the leading commercial solutions partner for life sciences companies, announced their collaborative program to simplify the channel for precision medicine therapies. Recognizing a significant unmet need for cell and gene therapy programs, as well as a deep pipeline of products that are set to launch over the next several years, PANTHERx® and RxCrossroads™ by McKesson are simplifying processes, coalescing strengths, gaining efficiencies, and creating a best-in-class portfolio for biopharma, provider, and payer partners.
“PANTHERx® is excited about partnering with RxCrossroads™ by McKesson in the rare disease and precision medicine space. This joint solution provides for more seamless and successful drug launches, increased speed to therapy, and enhanced patient satisfaction and outcomes,” said Dr. Gordon J. Vanscoy, chairman and chief executive officer of PANTHERx® Specialty Pharmacy. “Patients are at the center of everything that we do at PANTHERx®, so collaborating with a respected organization that shares our values is essential to us. We discovered a great match with RxCrossroads™ by McKesson, and we are confident that collectively, we will have measurable benefits for patients while enhancing the experiences of our biopharma partners.”
“RxCrossroads™ by McKesson is confident that together with PANTHERx® we will produce a successful logistics solution to assist our life sciences partners in the rare disease and precision medicine space through significant phases of their product life cycle,” said Kevin Kissling, vice president, Third-Party Logistics, RxCrossroads™ by McKesson. “We are committed to providing innovative solutions for stakeholders, including those focused on rare diseases and precision medicines, which is why we are excited to be working with PANTHERx®.”
With combined core strengths in specialty pharmacy for rare diseases, third-party logistics, access & adherence solutions, and safety monitoring services, the parties are confident that the collaborative offering will be the go-to solution for biopharma companies desiring an all-in-one commercialization approach for cell and gene therapies.
About PANTHERx® Specialty Pharmacy
PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, is the industry leading independent national specialty pharmacy headquartered in Pittsburgh, Pennsylvania. PANTHERx® Specialty’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Every day we create ways to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care®, by developing focused solutions, bold innovations, and novel clinical services associated with the life-transforming therapies that we deliver.
PANTHERx® was awarded 2018 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy as well as the American Pharmacy Purchasing Alliance. Zitter Health Insights awarded PANTHERx® the Specialty Pharmacy Patient Choice Award winner for both 2017 and 2018. Additionally, PANTHERx® was ranked #49 in the 2018 Inc. 5000 List of Fastest Growing Companies in the nation (top 100 for the last three years) and a Best Place to Work in Healthcare by Modern Healthcare magazine for 2018.
About RxCrossroads™ by McKesson
RxCrossroads™ by McKesson creates flexible, connected solutions for life sciences companies. Its solutions focus on increasing access, adherence, and safe use conditions, seamlessly connecting patients to their therapies, and enabling them to thrive at every step in their care journey. Through expert teams, deep market insights and innovative technology, RxCrossroads™ designs forward-thinking solutions that optimize the patient experience and positions its customers for success in every phase of the product life cycle. As part of McKesson Life Sciences, a business within McKesson Corporation, RxCrossroads™ harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.
To read the official press release, please click here: